Revised forecast
Fiscal year ending March 2027 · Six months and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Not a revision, but a newly disclosed forecast for the next fiscal year. While the company expects a challenging environment, including revisions to pharmaceutical companies' research and development plans, it expects demand for PXB mice to remain firm and has factored in higher outsourcing and other costs associated with the launch of PXB-cells in the United States.
Total extraordinary losses: ¥92 thousand (loss on liquidation of an affiliated company: ¥92 thousand; loss on disposal of fixed assets: ¥0 thousand)
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥1,610 million |
| Operating profit | Not disclosed → ¥85 million |
| Ordinary income | Not disclosed → ¥87 million |
| Profit attributable to owners of the parent | Not disclosed → ¥76 million |
| Net income per share | Not disclosed → 18.9 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months and full year |
| Previous-period results | Net sales of ¥1,565 million, operating income of ¥82 million, ordinary income of ¥131 million, net income attributable to owners of the parent of ¥125 million, and basic earnings per share of ¥30.81 |
| Reason for the revision | Not a revision, but a newly disclosed forecast for the next fiscal year. While the company expects a challenging environment, including revisions to pharmaceutical companies' research and development plans, it expects demand for PXB mice to remain firm and has factored in higher outsourcing and other costs associated with the launch of PXB-cells in the United States. |
| Details and amount of extraordinary loss | Total extraordinary losses: ¥92 thousand (loss on liquidation of an affiliated company: ¥92 thousand; loss on disposal of fixed assets: ¥0 thousand) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, overseas orders and net sales remained sluggish as major overseas customers continued to restrain research and development budgets, while sales of PXB mice to existing domestic customers increased. Expenses also declined following the liquidation of KMT Hepatech, Inc., which eliminated contract manufacturing costs, together with a reduction in the unit manufacturing cost of PXB mice. For the fiscal year ending March 2027, the company expects a challenging environment, including revisions to pharmaceutical companies' research and development plans, but expects demand for PXB mice to remain firm and has factored in higher outsourcing and other costs associated with the launch of PXB-cells in the United States.